Status:
UNKNOWN
Identification of Molecular Biomarkers for Thyroid Cancer
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Conditions:
Thyroid Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a two part study; part A proposes to collect plasma samples to examine how ctDNA (circulating thyroid DNA) markers correlate with detection of recurrent disease, response to therapy, clinical ...
Detailed Description
To collect blood and tumour tissue for Part A: molecular profiling, including extraction of DNA for sequencing, RNA for expression levels and to identify expressed fusion genes, and proteins for prote...
Eligibility Criteria
Inclusion
- T3-4, N0-1b, M0-M1 thyroid cancer (papillary, follicular, poorly differentiated, anaplastic and medullary thyroid carcinoma).
- Patient able to provide informed consent
- Patient attending the Royal Marsden Hospital for inpatient or outpatient review
- Sufficient tissue sample available to perform analysis (archived or fresh)
- Adults \>16 years old
Exclusion
- Patients unable to provide informed consent
- Thyroid lymphoma
- Metastases to the thyroid
- No histological confirmed diagnosis
- Only cytology available
Key Trial Info
Start Date :
December 21 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2020
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT04133870
Start Date
December 21 2015
End Date
July 30 2020
Last Update
October 21 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Marsden NHS Foundation Trust
London, Sutton, United Kingdom, SM2 5PT